[身体虚弱的治疗]
Deutsche medizinische Wochenschrift (1946)
|December 29, 2023
概括
虚弱是一种老年综合征,代表了残疾之前的可逆阶段. 早期治疗干预为改善老年人的功能限制提供了一个机会.
科学领域:
- 老年医学 老年医学
- 内部医学 内部医学
- 公共卫生 公共卫生
背景情况:
- 虚弱是一种显著的老年综合征.
- 它代表了功能自主和不可逆转的残疾之间的过渡阶段.
- 这个阶段为干预提供了一个关键的机会窗口.
研究的目的:
- 为提供治疗脆弱性的治疗方法的概述.
- 检查支持这些治疗的科学证据.
- 突出扭转功能限制的潜力.
主要方法:
- 对治疗虚弱的治疗干预的文献综述.
- 分析科学证据和临床试验数据.
- 综合关于脆弱性管理的当前研究.
主要成果:
- 存在各种治疗策略来管理脆弱性.
- 证据支持某些干预措施在改善功能方面的有效性.
- 早期治疗可以缓解残疾的进展.
结论:
- 虚弱是一种可以通过适当干预来治疗的疾病.
- 针对"机会之窗"对于老年护理至关重要.
- 需要进一步的研究来优化对脆弱的老年人治疗策略.
相关概念视频
Parkinson's Disease: Treatment
273
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
273
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Chest Physiotherapy
468
Chest Physiotherapy (CPT) is a therapeutic technique used in respiratory care to improve ventilation, clear bronchial secretions, and enhance the efficiency of respiratory muscles. This therapy includes three primary procedures: postural drainage, percussion, and vibration. It can be performed on spontaneously breathing patients and those who are intubated and mechanically ventilated.
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
468
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Muscle Recovery and Fatigue
2.1K
Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective...
2.1K
Flail Chest-II
175
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
175


